Loading…
Tandem Diabetes Care, Inc. is projected to decline to $18.82 by 2027, a -3% move from its current price of $19.50. TNDM is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $18.88 | $19.49 | $20.13 | -0.03% |
| Aug 3 | $18.63 | $19.49 | $20.39 | -0.07% |
| Aug 4 | $18.43 | $19.48 | $20.59 | -0.10% |
| Aug 5 | $18.27 | $19.47 | $20.76 | -0.13% |
| Aug 6 | $18.13 | $19.47 | $20.91 | -0.17% |
| Aug 7 | $18.00 | $19.46 | $21.04 | -0.20% |
| Aug 8 | $17.88 | $19.45 | $21.17 | -0.23% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $17.88 | $19.45 | $21.17 | -0.23% |
| Week 2 | $17.22 | $19.41 | $21.87 | -0.47% |
| Week 3 | $16.73 | $19.36 | $22.42 | -0.70% |
| Week 4 | $16.31 | $19.32 | $22.88 | -0.93% |
| Week 5 | $15.95 | $19.27 | $23.28 | -1.16% |
| Week 6 | $15.63 | $19.23 | $23.65 | -1.39% |
| Week 7 | $15.34 | $19.18 | $23.99 | -1.62% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. Its flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system.
The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, it offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data.
The company has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was incorporated in 2006 and is headquartered in San Diego, California. It was formerly known as Phluid Inc.
and changed its name to Tandem Diabetes Care, Inc. in January 2008.
Tandem Diabetes Care, Inc. (TNDM) trades at $18.59 per share, with a market cap of $1.27B and a rank of 2361.
Its 50-day simple moving average is $16.30 and the 200-day simple moving average is $18.96.
The near-term technical picture includes support at $14.34 and resistance at $18.59, with a 30-day range of $14.94 to $23.14. The current price context sits within a broader forecast that projects higher average prices in the years ahead.
A major floor 35.3% below — a decisive break under it would weaken the trend.
The nearest floor, 26.5% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 25.7% above — clearing it would confirm fresh momentum.
Key TNDM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TNDM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $18.41 | Buy | $18.61 | Buy |
| MA 10 | $17.87 | Buy | $17.95 | Buy |
| MA 20 | $16.79 | Buy | $17.25 | Buy |
| MA 50 | $16.52 | Buy | $17.01 | Buy |
| MA 100 | $18.12 | Buy | $17.65 | Buy |
| MA 200 | $19.01 | Buy | $18.58 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 68.46 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 163.96 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.33 | Buy |
| ROC (12) | 27.62 | Buy |
| Bollinger %B (20,2) | 1.02 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.33 | Buy |
| Awesome (5,34) | 2.10 | Buy |
| Ultimate (7,14,28) | 87.26 | Sell |
| Momentum (10) | 2.42 | Buy |
| Aroon Osc (25) | 88.00 | Buy |
| Hull MA (9) | 19.26 | Buy |
| ADX (14) | 16.23 | Neutral |
| ATR (14) | 0.51 | Info |
Technical sentiment is BULLISH and the RSI14 is 60.
The stock trades near resistance at $18.59 and near support at $14.34, with a 30-day range of $14.94 to $23.14. The 50-day SMA is $16.30 and the 200-day SMA is $18.96.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $12.82 | $19.50 | $22.87 | 0% | Neutral | |
| $14.78 | $18.82 | $25.48 | -3% | Neutral | |
| $14.69 | $19.35 | $27.35 | -1% | Neutral | |
| $15.97 | $21.64 | $31.61 | +11% | Neutral | |
| $18.33 | $25.44 | $38.22 | +30% | Bullish | |
| $19.85 | $28.19 | $43.38 | +45% | Bullish | |
| $20.62 | $29.91 | $47.03 | +53% | Bullish | |
| $19.24 | $28.45 | $45.62 | +46% | Bullish | |
| $19.47 | $29.35 | $47.90 | +50% | Bullish | |
| $21.37 | $32.80 | $54.43 | +68% | Bullish | |
| $27.82 | $46.40 | $82.51 | +138% | Bullish | |
| $44.42 | $85.75 | $168.45 | +340% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $12.82 | $19.50 | $23.36 | +0.00% |
| September 2026 | $15.80 | $18.79 | $23.04 | -3.64% |
| October 2026 | $15.78 | $18.92 | $23.49 | +0.67% |
| November 2026 | $15.67 | $18.91 | $23.71 | -0.04% |
| December 2026 | $14.89 | $18.08 | $22.87 | -4.39% |
Click any year to see its month-by-month TNDM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Tandem Diabetes Care, Inc.'s 2026 outlook centres on $19.50, within a $12.82 to $22.87 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, TNDM could reach as high as $25.48, with a base case around $18.82 and support toward $14.78 — roughly -3% from $19.50. A consolidation phase looks the most probable path here.
Expect TNDM to range from $14.69 to $27.35 through 2028. The $19.35 average target implies a -1% move from current prices. That is up +3% on the projected 2027 average. Price action looks broadly range-bound.
The TNDM price prediction for 2029 points to an average of $21.64 (low $15.97, high $31.61) — a potential gain of +11% on today's $19.50. A consolidation phase looks the most probable path here.
In 2030, TNDM is projected to trade between $18.33 and $38.22, averaging $25.44 — a potential gain of +30% from today's $19.50. That is up +18% on the projected 2029 average. Momentum favours further upside here.
Tandem Diabetes Care, Inc.'s 2031 outlook centres on $28.19, within a $19.85 to $43.38 range. That is up +11% on the projected 2030 average. That marks a +45% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, TNDM could reach as high as $47.03, with a base case around $29.91 and support toward $20.62 — roughly +53% from $19.50. Momentum favours further upside here.
Expect TNDM to range from $19.24 to $45.62 through 2033. The $28.45 average target implies a +46% move from current prices. That is -5% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
The TNDM price prediction for 2034 points to an average of $29.35 (low $19.47, high $47.90) — a potential gain of +50% on today's $19.50. Momentum favours further upside here.
In 2035, TNDM is projected to trade between $21.37 and $54.43, averaging $32.80 — a potential gain of +68% from today's $19.50. That is up +12% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Tandem Diabetes Care, Inc.'s 2040 outlook centres on $46.40, within a $27.82 to $82.51 range. That is up +41% on the projected 2035 average. That marks a +138% change versus current levels. Momentum favours further upside here.
By 2050, TNDM could reach as high as $168.45, with a base case around $85.75 and support toward $44.42 — roughly +340% from $19.50. Buyers look set to stay in control over this stretch.
Investing $1,000 in TNDM today (≈ 51.282051 TNDM) could be worth
$4,397.44
+$3,397.44 (+340%) by 2050 · US Dollar
Based on the average projected TNDM price of $85.75 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TNDMwould be worth at today's price.
$1,000 invested in TNDM on Jul 31, 2025 (≈ 64.184853 TNDM) would be worth
$1,251.6
+$251.6 (+25.2%) today · 1.25× · US Dollar
Based on a TNDM entry price of $15.58 vs. today's $19.5.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $17.12 | $1,139.02 | +13.9% |
| 1 month ago | $15.75 | $1,238.1 | +23.8% |
| 3 months ago | $19.42 | $1,004.12 | +0.4% |
| 6 months ago | $20.09 | $970.63 | -2.9% |
| 1 year ago | $15.58 | $1,251.6 | +25.2% |
| All time (5.0y) ago | $106.62 | $182.89 | -81.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TNDM forecast.
Our base-case forecast reaches $39.00 around 2040.
Implied market cap at $39.00: $2.67B
The multi-year forecast shows a bullish path beyond 2026, with the 2030 average price at $23.49 and a 26.4% ROI. The 2040 average price is $41.59 with a 123.7% ROI, and the 2050 average price is $76.12 with a 309.5% ROI.
In 2027 and 2028, the forecast includes negative ROI values of -4.6% and -3.1% respectively, before turning positive again in 2029 (+6.9%) and continuing higher in later years. The 2031–2035 years show continued bullish momentum with rising averages and double-digit ROIs, culminating in substantial long-run upside in 2040 and 2050. These projections imply a higher price path but come with the inherent uncertainty of forward-looking estimates.
Tap a question to reveal the answer.
Avg $23.49; min $16.78; max $35.60; ROI 26.4%; sentiment BULLISH.
The forecast shows neutral sentiment in 2026-2029 with small or negative ROIs in 2027 (-4.6) and 2028 (-3.1) before turning bullish from 2030 onward (e.g., ROI 26.4% in 2030). These are estimates, not guarantees, and depend on future conditions.
Yes, the forecast allows a max of $151.94 by 2050, with bullish momentum continuing through the period.
Current price is $18.59 and market cap is $1.27B.
Low is $14.94 and high is $23.14.
Tandem Diabetes Care, Inc. Community Discussion
0Share your Tandem Diabetes Care, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.